Screener
Relay Therapeutics, Inc. RLAY Proceeds From Issuance Of Common Stock Through Exercise Of Stock Options
Proceeds From Issuance Of Common Stock Through Exercise Of Stock Options at other companies
Other financials
Where this comes from
Reported directly by Relay Therapeutics, Inc. in its filing.
Tagged under the XBRL concept rlay:ProceedsFromIssuanceOfCommonStockThroughExerciseOfStockOptions.
The source filing: Relay Therapeutics, Inc.’s 10-K, filed February 26, 2026. Open the filing →
- Filed
- Feb 25, 2026, 7:00 PM EST
- Fiscal year
- FY2025
- Accession
- 0001193125-26-076739
FAQ
- What is Relay Therapeutics, Inc.'s proceeds from issuance of common stock through exercise of stock options?
- Relay Therapeutics, Inc. (RLAY) reported proceeds from issuance of common stock through exercise of stock options of $131K in Q4 2025.
- How has Relay Therapeutics, Inc.'s proceeds from issuance of common stock through exercise of stock options changed year-over-year?
- Relay Therapeutics, Inc.'s proceeds from issuance of common stock through exercise of stock options decreased by 81.2% year-over-year, from $695.5K to $131K.
- What is the long-term trend for Relay Therapeutics, Inc.'s proceeds from issuance of common stock through exercise of stock options?
- Over 3 years (2022 to 2025), Relay Therapeutics, Inc.'s proceeds from issuance of common stock through exercise of stock options has grown at a -46.8% compound annual growth rate (CAGR), from $3.48M to $524K.
- What does proceeds from issuance of common stock through exercise of stock options mean?
- Proceeds From Issuance Of Common Stock Through Exercise Of Stock Options as reported by Relay Therapeutics, Inc. Common Stock.
Ask your AI about Relay Therapeutics, Inc.'s proceeds from issuance of common stock through exercise of stock options.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude